VINC: Vincerx Pharma, Inc. Stock

by  •  • Comments Off on VINC: Vincerx Pharma, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 23.70
Enterprise Value ($M) 10.92
Book Value ($M) 11.22
Book Value / Share 0.38
Price / Book 2.11
NCAV ($M) 7.74
NCAV / Share 0.26
Price / NCAV 3.06

Profitability (mra)
Return on Invested Capital (ROIC) -2.93
Return on Assets (ROA) -0.85
Return on Equity (ROE) -1.17

Liquidity (mrq)
Quick Ratio 2.63
Current Ratio 2.63

Balance Sheet (mrq) ($M)
Current Assets 14.73
Assets 18.22
Liabilities 7.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -42.61
Net Income -40.16
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -40.45
Cash from Investing 41.50
Cash from Financing 0.11

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
8 days ago 13G Prosight Management, LP 9.10
04-09 13G/A Goldman Sachs Group Inc 3.00 -63.06
02-14 13G/A Long Focus Capital Management, Llc 5.10 -22.35
02-13 13G/A Affinity Asset Advisors, LLC 0.00 -100.00
02-13 13G Bank Of America Corp /de/ 5.10

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PUR
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION R
2023-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-10 108,230 430,841 25.12
2024-05-09 31,896 84,862 37.59
2024-05-08 26,904 42,939 62.66
2024-05-07 38,747 50,418 76.85
2024-05-06 46,962 21,925 214.19

(click for more detail)

Similar Companies
VBIV – VBI Vaccines Inc. VCNX – Vaccinex, Inc.
VERU – Veru Inc. VIRI – Virios Therapeutics, Inc.
VKTX – Viking Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io